REG - Malin Corp PLC - Immunocore appoints Chief Executive Officer

MalinAnnouncement

07/01/2019 07:05

RNS Number : 3036M
Malin Corporation PLC
07 January 2019
 


 
Malin Corporation plc
 
("Malin")
 
Immunocore appoints Bahija Jallal as Chief Executive Officer
 
-     Malin owns approximately 10% of Immunocore, a Malin Priority Portfolio Asset -
 
Dublin-Ireland, 7 January 2019: Malin Corporation plc (ISE:MLC), a company investing in highly innovative life sciences companies, is pleased to note that Immunocore has appointed Bahija Jallal as Chief Executive Officer and Director of the Board.
 
Bahija Jallal joins from AstraZeneca where she was President and head of its global biologics research and development unit, MedImmune. She was a member of the senior executive team at AstraZeneca reporting to the CEO.  During her time at MedImmune, she oversaw significant growth in the AstraZeneca biologics pipeline across a range of disease areas.  
 
"Bahija Jallal's appointment as CEO of Immunocore strengthens the company's  management team and signals that it is entering a period of significant clinical and commercial maturity," said Jean-Michel Cossery, Non-Executive Director of Malin and Malin's Immunocore Board designate. "With significant leadership experience and an impressive scientific pedigree, she is ideally suited to lead Immunocore at this exciting time as it focuses on the approaching Biologics License Application submission for its lead asset, IMCgp100 and progressing its broad pipeline. Immunocore is a Malin Priority Portfolio Asset and Bahija's appointment will support this company's momentum towards the creation of value for patients and investors." 
 
Malin owns approximately 10% of Immunocore and carried its investment in Immunocore at €85.1 million at 30 June 2018 in its portfolio fair value estimate under International Private Equity Valuation guidelines.
 
A copy of Immunocore's press release is available to view here: https://www.immunocore.com/news-hub/news 
 
ENDS
 
For further information, please contact:
 
Malin
Jessica Bergin, Director of Investor Relations & External Reporting
Tel: +353 (0)1 901 5700
investorrelations@malinplc.com
 
 
 
Consilium Strategic Communications (Financial PR)
Mary-Jane Elliott / Jonathan Birt
Tel: +44 (0)20 3709 5700
malin@consilium-comms.com
 
Powerscourt (Ireland PR)           
Eavan Gannon                                              
Tel: +353 87 236 5973                            
malin@powerscourt-group.com                                                                          
 
Davy Corporate Finance (ESM Adviser)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
 
About Malin Corporation plc
Malin (ISE:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on Euronext Dublin. For more information visit www.malinplc.com 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUGURAGUPBPGQ